Expression of galectins in cancer: A critical review

A large body of literature has examined and described galectin expression in cancer. Discrepancies have been observed in the reported data, which hampered clear understanding of the expression profiles. This relates to the use of different types of methods that evaluate either global or specific gene expression in heterogeneous cancer tissue samples, type of antibodies used in immunohistochemistry and procedures of comparison of gene expression. In this manuscript, we review the main data concerning expression of galectins in human cancer. Only galectin-1 and galectin-3, the most abundant and examined galectins, will be examined here. Published in 2004.

[1]  N. Berger,et al.  Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. , 1992, Oncogene.

[2]  Ashu Sharma,et al.  Role of galaptin in ovarian carcinoma adhesion to extracellular matrix in vitro , 1990, Journal of cellular biochemistry.

[3]  P. De Giuli,et al.  Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  J. L. Wang,et al.  Carbohydrate-binding protein 35. Levels of transcription and mRNA accumulation in quiescent and proliferating cells. , 1989, The Journal of biological chemistry.

[5]  Z. Baloch,et al.  Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.

[6]  R. Kiss,et al.  Galectin‐1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma , 2001, Glia.

[7]  Y. Vaishnav,et al.  Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. , 2002, The Journal of clinical endocrinology and metabolism.

[8]  J. Hirabayashi,et al.  Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. , 2001, Human pathology.

[9]  K. Mishima,et al.  Expression of galectin‐1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin‐1 inhibits the growth of 9 glioma cells , 2000, Journal of neuroscience research.

[10]  M. Kurimoto,et al.  Involvement of galectin-3 expression in colorectal cancer progression and metastasis. , 1999, International journal of oncology.

[11]  V. Castronovo,et al.  Decreased expression of galectin-3 in basal cell carcinoma of the skin. , 1999, International journal of oncology.

[12]  T. Springer,et al.  Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. , 1982, Journal of immunology.

[13]  K. Nabeshima,et al.  Diagnostic utility of galectin‐3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules , 2002, Diagnostic cytopathology.

[14]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.

[15]  L. Frigeri,et al.  Surface expression of functional IgE binding protein, an endogenous lectin, on mast cells and macrophages. , 1992, Journal of immunology.

[16]  A. Schauer,et al.  Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas , 1986, Virchows Archiv. B, Cell pathology including molecular pathology.

[17]  A. Hölscher,et al.  Increased Galectin-3 Expression in Gastric Cancer: Correlations with Histopathological Subtypes, Galactosylated Antigens and Tumor Cell Proliferation , 2000, Tumor Biology.

[18]  M. P. Martegani,et al.  Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Bast,et al.  Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. , 1996, Human pathology.

[20]  R. Lotan,et al.  Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. , 1991, Cancer research.

[21]  P. Pour,et al.  Localization of galectin-3 in normal and diseased pancreatic tissue , 1998, International journal of pancreatology : official journal of the International Association of Pancreatology.

[22]  E. Campo,et al.  GALECTIN‐3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON‐NEOPLASTIC THYROID TISSUE , 1997, The Journal of pathology.

[23]  S. Savin,et al.  Galectin‐3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression , 2000, Histopathology.

[24]  Tatjana Crnogorac-Jurcevic,et al.  Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. , 2002, The American journal of pathology.

[25]  C. Lohse,et al.  Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1 , 2003, Endocrine pathology.

[26]  A. Fusco,et al.  Expression of galectin‐1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors , 1995, International journal of cancer.

[27]  J. L. Wang,et al.  Identification of carbohydrate binding protein 35 in heterogeneous nuclear ribonucleoprotein complex. , 1988, Biochemistry.

[28]  F. Marshall,et al.  Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. , 2001, The American journal of pathology.

[29]  R. Kiss,et al.  The levels of expression of galectin‐1, galectin‐3, and the Thomsen–Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers , 1999, Cancer.

[30]  E. Campo,et al.  Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. , 1992, Journal of the National Cancer Institute.

[31]  R. Lotan,et al.  Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer , 1999, Urological Research.

[32]  J. L. Wang,et al.  Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Niedziela,et al.  Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. , 2002, The Journal of clinical endocrinology and metabolism.

[34]  本城 祐一郎.  Expression of Cytoplasmic Galectin-3 as a Prognostic Marker in Tongue Carcinoma , 2001 .

[35]  John L. Wang,et al.  Identification of galectin-3 as a factor in pre-mRNA splicing. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Kimura,et al.  Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[37]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[38]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in benign and malignant salivary gland neoplasms. , 2000, International Journal of Oncology.

[39]  R. Lotan,et al.  Transformation‐related changes in the expression of endogenous cell lectins , 1987, International journal of cancer.

[40]  R. Gaffney,et al.  Galectin-3 Expression in Hyalinizing Trabecular Tumors of the Thyroid Gland , 2003, The American journal of surgical pathology.

[41]  N. Petrelli,et al.  Localization of Endogenous β-Galactoside-Binding Lectin in Human Cells and Tissues , 1991 .

[42]  S. Raphael.  The meanings of markers: Ancillary techniques in diagnosis of thyroid neoplasia , 2002, Endocrine pathology.

[43]  R. Bast,et al.  Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. , 1994, European journal of cancer.

[44]  A. Longatto-Filho,et al.  Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas , 2001, Endocrine pathology.

[45]  V. Castronovo,et al.  Alteration of the cytoplasmic/nuclear expression pattern of galectin‐3 correlates with prostate carcinoma progression , 2000 .

[46]  M. Papotti,et al.  Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma. , 2002, European journal of endocrinology.

[47]  M. Beesley,et al.  Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules , 2002, Histopathology.

[48]  Q. Sun,et al.  Carbohydrate-binding protein 35. I. Properties of the recombinant polypeptide and the individuality of the domains. , 1993, The Journal of biological chemistry.

[49]  T. Yoshii,et al.  Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.

[50]  G. Benvenuto,et al.  Galectin‐1 and galectin‐3 expression in human bladder transitional‐cell carcinomas , 1999, International journal of cancer.

[51]  S. Savin,et al.  Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. , 1998, Anticancer research.

[52]  A. Avivi,et al.  Cloning and expression of cDNA for two endogenous UV-2237 fibrosarcoma lectin genes. , 1987, Experimental cell research.

[53]  F. Negro,et al.  Galectin‐3, a marker of well‐differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia , 2002, Histopathology.

[54]  P. De Giuli,et al.  Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.

[55]  R. Lotan,et al.  Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. , 1991, Carbohydrate research.

[56]  J. L. Wang,et al.  Endogenous lectins from cultured cells: subcellular localization of carbohydrate-binding protein 35 in 3T3 fibroblasts , 1986, The Journal of cell biology.

[57]  S. Natsugoe,et al.  Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. , 2000, Human pathology.

[58]  Jung‐Ta Chen,et al.  Galectin‐3 expression is induced in cirrhotic liver and hepatocellular carcinoma , 1999, International journal of cancer.

[59]  Salmon,et al.  Galectin‐3 and galectin‐3‐binding site expression in human adult astrocytic tumours and related angiogenesis , 1999, Neuropathology and applied neurobiology.

[60]  H. Friess,et al.  Comparative Analysis of Galectins in Primary Tumors and Tumor Metastasis in Human Pancreatic Cancer , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[61]  E. Campo,et al.  Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. , 1997, Gastroenterology.

[62]  H. Inohara,et al.  Galectin-3 is a nuclear matrix protein which binds RNA. , 1995, Biochemical and biophysical research communications.

[63]  V. Castronovo,et al.  Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell–cell adhesion , 2004, Angiogenesis.

[64]  L. Baum,et al.  Apoptosis of T cells mediated by galectin-1 , 1995, Nature.

[65]  A. Raz,et al.  Expression of two different endogenous galactoside-binding lectins sharing sequence homology. , 1988, Cancer research.

[66]  W. Hopfenmüller,et al.  [Expression of galectin-3 in thyroid gland and follicular cell tumors of the thyroid. A critical study of its possible role in preoperative differential diagnosis]. , 2001, Der Pathologe.

[67]  R. Lotan,et al.  Expression of a 31‐kDa lactoside‐binding lectin in normal human gastric Mucosa and in primary and metastatic gastric carcinomas , 1994, International journal of cancer.

[68]  E. Baudin,et al.  Differential expression of galectin‐3 in medullary thyroid carcinoma and C‐cell hyperplasia , 2002, Clinical endocrinology.

[69]  J. L. Wang,et al.  Carbohydrate-binding protein 35. Isoelectric points of the polypeptide and a phosphorylated derivative. , 1990, The Journal of biological chemistry.

[70]  R. Lotan,et al.  Expression of galectins in head and neck squamous cell carcinoma , 1996, Head & neck.

[71]  Edward A. Lee,et al.  Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Fu-Tong Liu,et al.  Expression of ɛBP, a β‐galactoside‐binding soluble lectin, in normal and neoplastic epidermis , 1994 .

[73]  V. Castronovo,et al.  DECREASED EXPRESSION OF GALECTIN‐3 IS ASSOCIATED WITH PROGRESSION OF HUMAN BREAST CANCER , 1996, The Journal of pathology.

[74]  V. Castronovo,et al.  Increased expression of galectin‐1 in carcinoma‐associated stroma predicts poor outcome in prostate carcinoma patients , 2001, The Journal of pathology.

[75]  M. Papotti,et al.  Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. , 2003, The Journal of clinical endocrinology and metabolism.

[76]  R. Bresalier,et al.  Expression of the endogenous galactose‐binding protein galectin‐3 correlates with the malignant potential of tumors in the central nervous system , 1997, Cancer.

[77]  V. Hogan,et al.  Decreased galectin‐3 expression in prostate cancer , 2000, The Prostate.